RANDOMIZED TRIAL BETWEEN SELECTIVE AROMATASE INHIBITOR FORMESTANE ((R)LENTARON) VS TAMOXIFEN AS FIRST-LINE HORMONAL-THERAPY IN POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER - CONFIRMATION OF BIOEQUIVALENCE IN SURVIVAL

Authors
MAURIAC L CARRION RP ALBEROLA V CALABRESI F MICHEL RT SANTOS R WEHRLE E ROYCE CM
Citation
L. Mauriac et al., RANDOMIZED TRIAL BETWEEN SELECTIVE AROMATASE INHIBITOR FORMESTANE ((R)LENTARON) VS TAMOXIFEN AS FIRST-LINE HORMONAL-THERAPY IN POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER - CONFIRMATION OF BIOEQUIVALENCE IN SURVIVAL, European journal of cancer, 31A, 1995, pp. 365-365
Citations number
NO
Categorie Soggetti
Oncology
Journal title
European journal of cancer → ACNP
ISSN journal
09598049
Volume
31A
Year of publication
1995
Supplement
5
Pages
365 - 365
Database
ISI
SICI code
0959-8049(1995)31A:<365:RTBSAI>2.0.ZU;2-C